Erdoğan Özdemir
Erdoğan Özdemir has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Erman Özdemir
Pendik Devlet Hastanesi
5 shared publications - Pınar Özdemir
UNIVERSITY OF HEALTH SCIENCES, İSTANBUL KARTAL DR. LÜTFİ KIRDAR HEALTH RESEARCH CENTER
4 shared publications Turgay Yılmaz
Department of Internal Medicine, Elazığ Fethi Sekin City Hospital
3 shared publicationsDeccane Düzenci
Department of Intensive Care Unit, Elazığ Fethi Sekin City Hospital
2 shared publications- Serap Yadigar
Department of Nephrology, University of Health Sciences, Hamidiye International School of Medicine, Kartal, Dr. Lütfi Kırdar City Hospital, Istanbul, Türkiye
2 shared publications - Abdurrahman Yılmaz
Department of Chest Diseases, Sancaktepe İlhan Varank Training and Research Hospital, Health Sciences University, Istanbul, Türkiye
1 shared publication
Latest Publications
- 30 September 2026
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 12 (3) , 305-310
METABOLIC ALKALOSIS AND MICROSCOPIC HEMATURIA IN SYNTHETIC CANNABINOID-ASSOCIATED ACUTE KIDNEY INJURY: A FREQUENCY-MATCHED COMPARATIVE STUDY
Objective: Synthetic cannabinoid-associated acute kidney injury (SC-AKI) is difficult to recognize because routine toxicology may not detect emerging compounds and exposure may initially be undisclosed. We evaluated whether metabolic alkalosis and microscopic hematuria identify a distinct clinical pattern among young adults with severe AKI.Methods: This single-center retrospective frequency-matched study included patients aged 18-45 years with KDIGO stage 3 AKI evaluated between January 2016 and December 2023. Eleven patients with probable SC-AKI were compared with 44 non-SC AKI controls matched by sex, age distribution, admission creatinine, and peak creatinine. Fisher exact and Mann-Whitney U tests were used.Results: Median age was 34 versus 35 years and admission creatinine was 5.9 versus 6.25 mg/dL. Metabolic alkalosis occurred in 7/11 SC-AKI patients and 5/44 controls (p
- 30 September 2026
- Published by Kocaeli Universitesi Saglik Bilimleri Dergisi in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
- Vol. 12 (3) , 305-310
METABOLIC ALKALOSIS AND MICROSCOPIC HEMATURIA IN SYNTHETIC CANNABINOID-ASSOCIATED ACUTE KIDNEY INJURY: A FREQUENCY-MATCHED COMPARATIVE STUDY
Objective: Synthetic cannabinoid-associated acute kidney injury (SC-AKI) is difficult to recognize because routine toxicology may not detect emerging compounds and exposure may initially be undisclosed. We evaluated whether metabolic alkalosis and microscopic hematuria identify a distinct clinical pattern among young adults with severe AKI.Methods: This single-center retrospective frequency-matched study included patients aged 18-45 years with KDIGO stage 3 AKI evaluated between January 2016 and December 2023. Eleven patients with probable SC-AKI were compared with 44 non-SC AKI controls matched by sex, age distribution, admission creatinine, and peak creatinine. Fisher exact and Mann-Whitney U tests were used.Results: Median age was 34 versus 35 years and admission creatinine was 5.9 versus 6.25 mg/dL. Metabolic alkalosis occurred in 7/11 SC-AKI patients and 5/44 controls (p
- Open Access
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1896542
Serum phoenixin-14 levels in chronic kidney disease and hemodialysis patients: a cross-sectional study
Background: Phoenixin-14 (PNX-14) is a bioactive peptide associated with mitochondrial function, oxidative stress responses, and cellular protection. Although experimental data suggest a possible role in renal injury, its serum levels in chronic kidney disease (CKD) have not been previously studied. Given the limitations of conventional renal biomarkers, PNX-14 may offer additional information regarding renal dysfunction in CKD. Methods: This single-center, prospective, observational, cross-sectional study included 140 adult patients with Stage 3 CKD ( n = 30), Stage 4 CKD ( n = 30), Stage 5 CKD ( n = 30), and end-stage kidney disease receiving maintenance hemodialysis (HD) ( n = 50). Serum PNX-14 was measured using a commercial ELISA kit, before and after dialysis in HD patients. Associations between PNX-14 and clinical and laboratory parameters were assessed using Spearman correlation. Receiver operating characteristic (ROC) curve analysis evaluated the discriminative performance of PNX-14 across CKD stages. Results: Serum PNX-14 levels increased progressively with advancing CKD stage, from a median of 17.88 (IQR 15.16–20.20) pg/mL in Stage 3–43.14 (IQR 23.78–95.71) pg/mL in the HD group ( p < 0.001). Post hoc analysis showed that PNX-14 levels were significantly lower in Stage 3 than in Stage 5 and HD, in Stage 4 than in HD, and in Stage 5 than in HD. PNX-14 showed significant positive correlations with creatinine and parathyroid hormone (PTH) and a significant negative correlation with eGFR (all p < 0.001). In the pre-dialysis subgroup, PNX-14 remained significantly correlated with creatinine, eGFR, urea, and PTH. In HD patients, no significant difference was observed between pre-dialysis and post-dialysis PNX-14 levels ( p = 0.152), and no significant correlation was found between PNX-14 and Kt/V. ROC analysis demonstrated good discriminative performance for distinguishing Stage 3 from advanced disease (Stage 5 + HD), with an AUC of 0.839 (95% CI: 0.755–0.913). The optimal cut-off was 19.59 pg/mL, with 87.5% sensitivity and 73.3% specificity. Conclusions: Serum PNX-14 levels increase with worsening CKD stage and are strongly associated with renal function parameters. Its limited change after HD and its discriminative performance suggest that PNX-14 may provide clinically relevant information regarding disease severity in CKD. Further prospective and longitudinal studies are needed to clarify its potential clinical utility.
- 7 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1896542
Open AccessSerum phoenixin-14 levels in chronic kidney disease and hemodialysis patients: a cross-sectional study
Background: Phoenixin-14 (PNX-14) is a bioactive peptide associated with mitochondrial function, oxidative stress responses, and cellular protection. Although experimental data suggest a possible role in renal injury, its serum levels in chronic kidney disease (CKD) have not been previously studied. Given the limitations of conventional renal biomarkers, PNX-14 may offer additional information regarding renal dysfunction in CKD. Methods: This single-center, prospective, observational, cross-sectional study included 140 adult patients with Stage 3 CKD ( n = 30), Stage 4 CKD ( n = 30), Stage 5 CKD ( n = 30), and end-stage kidney disease receiving maintenance hemodialysis (HD) ( n = 50). Serum PNX-14 was measured using a commercial ELISA kit, before and after dialysis in HD patients. Associations between PNX-14 and clinical and laboratory parameters were assessed using Spearman correlation. Receiver operating characteristic (ROC) curve analysis evaluated the discriminative performance of PNX-14 across CKD stages. Results: Serum PNX-14 levels increased progressively with advancing CKD stage, from a median of 17.88 (IQR 15.16–20.20) pg/mL in Stage 3–43.14 (IQR 23.78–95.71) pg/mL in the HD group ( p < 0.001). Post hoc analysis showed that PNX-14 levels were significantly lower in Stage 3 than in Stage 5 and HD, in Stage 4 than in HD, and in Stage 5 than in HD. PNX-14 showed significant positive correlations with creatinine and parathyroid hormone (PTH) and a significant negative correlation with eGFR (all p < 0.001). In the pre-dialysis subgroup, PNX-14 remained significantly correlated with creatinine, eGFR, urea, and PTH. In HD patients, no significant difference was observed between pre-dialysis and post-dialysis PNX-14 levels ( p = 0.152), and no significant correlation was found between PNX-14 and Kt/V. ROC analysis demonstrated good discriminative performance for distinguishing Stage 3 from advanced disease (Stage 5 + HD), with an AUC of 0.839 (95% CI: 0.755–0.913). The optimal cut-off was 19.59 pg/mL, with 87.5% sensitivity and 73.3% specificity. Conclusions: Serum PNX-14 levels increase with worsening CKD stage and are strongly associated with renal function parameters. Its limited change after HD and its discriminative performance suggest that PNX-14 may provide clinically relevant information regarding disease severity in CKD. Further prospective and longitudinal studies are needed to clarify its potential clinical utility.
- Open Access
- 21 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0354233
Limited diagnostic utility of albumin-corrected calcium in the intensive care unit: A prospective comparison with ionised calcium
Background: Albumin-adjusted calcium is widely used despite uncertainty about its accuracy in critically ill adults. We prospectively evaluated the diagnostic performance of total calcium and of multiple published albumin-correction formulae against ionised calcium, the physiological reference standard, in an intensive care unit (ICU) cohort. Methods: In this prospective observational cohort study, ionised calcium (iCa), total calcium, albumin, venous pH, creatinine, estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), procalcitonin, magnesium, phosphate and vitamin D were measured simultaneously. The primary outcome was the diagnostic accuracy (area under the ROC curve [AUC]; sensitivity/specificity) of total calcium and of corrected calcium for detecting hypocalcaemia, defined a priori by the reference standard as iCa < 1.12 mmol/L; the pre-specified contrast was the difference between the two correlated AUCs. Twelve published measures were compared (total calcium; Payne; simplified Payne; Orrell; Berry; James; Jain; Thode; and the Pekar and Antonio estimators). Agreement, formal subgroup interaction tests, an explanatory multivariable model with collinearity diagnostics, and an exploratory internally-validated ICU equation were assessed. Results: In total, 250 patients were enrolled (median age 70 years; 147 men, 58.8%). Hypocalcaemia prevalence was 58.0% (n = 145). Payne-corrected calcium correctly identified only 15.2% of truly hypocalcaemic patients (Cohen κ = 0.08), versus 62.8% for total calcium (κ = 0.40). No simple albumin-correction formula significantly outperformed unadjusted total calcium (AUC 0.69–0.75; all DeLong p > 0.05 vs total calcium AUC 0.74). Only the four-variable Pekar estimator achieved a higher AUC (0.78; p = 0.005). In the explanatory model, only total calcium, pH, and sex independently predicted iCa (all variance inflation factors < 1.8); albumin, phosphate and vitamin D were not significant. An exploratory ICU-specific equation reached an optimism-corrected R² of only 0.17. Conclusions: Albumin-corrected calcium, including all established formulae tested, provides no diagnostic benefit over total calcium in the ICU and frequently masks true hypocalcaemia. Direct ionised-calcium measurement should be prioritised when accurate calcium status affects management. These are diagnostic-accuracy findings; their clinical-outcome implications require outcome-anchored study.
- 21 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0354233
Open AccessLimited diagnostic utility of albumin-corrected calcium in the intensive care unit: A prospective comparison with ionised calcium
Background: Albumin-adjusted calcium is widely used despite uncertainty about its accuracy in critically ill adults. We prospectively evaluated the diagnostic performance of total calcium and of multiple published albumin-correction formulae against ionised calcium, the physiological reference standard, in an intensive care unit (ICU) cohort. Methods: In this prospective observational cohort study, ionised calcium (iCa), total calcium, albumin, venous pH, creatinine, estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), procalcitonin, magnesium, phosphate and vitamin D were measured simultaneously. The primary outcome was the diagnostic accuracy (area under the ROC curve [AUC]; sensitivity/specificity) of total calcium and of corrected calcium for detecting hypocalcaemia, defined a priori by the reference standard as iCa < 1.12 mmol/L; the pre-specified contrast was the difference between the two correlated AUCs. Twelve published measures were compared (total calcium; Payne; simplified Payne; Orrell; Berry; James; Jain; Thode; and the Pekar and Antonio estimators). Agreement, formal subgroup interaction tests, an explanatory multivariable model with collinearity diagnostics, and an exploratory internally-validated ICU equation were assessed. Results: In total, 250 patients were enrolled (median age 70 years; 147 men, 58.8%). Hypocalcaemia prevalence was 58.0% (n = 145). Payne-corrected calcium correctly identified only 15.2% of truly hypocalcaemic patients (Cohen κ = 0.08), versus 62.8% for total calcium (κ = 0.40). No simple albumin-correction formula significantly outperformed unadjusted total calcium (AUC 0.69–0.75; all DeLong p > 0.05 vs total calcium AUC 0.74). Only the four-variable Pekar estimator achieved a higher AUC (0.78; p = 0.005). In the explanatory model, only total calcium, pH, and sex independently predicted iCa (all variance inflation factors < 1.8); albumin, phosphate and vitamin D were not significant. An exploratory ICU-specific equation reached an optimism-corrected R² of only 0.17. Conclusions: Albumin-corrected calcium, including all established formulae tested, provides no diagnostic benefit over total calcium in the ICU and frequently masks true hypocalcaemia. Direct ionised-calcium measurement should be prioritised when accurate calcium status affects management. These are diagnostic-accuracy findings; their clinical-outcome implications require outcome-anchored study.
- Open Access
- 13 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5483
Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study
Background/Objectives: Secondary hyperparathyroidism is a frequent component of chronic kidney disease-mineral and bone disorder in maintenance hemodialysis. Calcitriol and paricalcitol are used to suppress intact parathyroid hormone (iPTH), but the comparative advantage of paricalcitol in routine practice remains uncertain. This study compared 6-month biochemical PTH control in patients treated with intravenous calcitriol or intravenous paricalcitol. Methods: In this single-center retrospective cohort study, 312 adult hemodialysis patient files from 2023 to 2025 were screened. Patients who did not receive either intravenous study agent, switched between agents, or did not complete 6 months of treatment with the same agent were excluded. The final cohort included 185 patients, 100 treated with calcitriol and 85 with paricalcitol. The primary endpoint was target iPTH at 6 months, defined as 150–600 pg/mL. Results: Mean age was 58.9 ± 13.6 years, and 106 patients were male. Baseline iPTH was similar in the calcitriol and paricalcitol groups (684 ± 268 vs. 712 ± 291 pg/mL; p = 0.498). At 6 months, iPTH decreased significantly in both groups, with no significant between-group difference in follow-up iPTH (421 ± 214 vs. 398 ± 205 pg/mL; p = 0.456), percentage iPTH reduction (−36.8 ± 22.4% vs. −39.5 ± 24.1%; p = 0.431), or target iPTH achievement (62.0% vs. 60.0%; p = 0.781). Hypercalcemia and hyperphosphatemia rates were also similar. In multivariable analysis, treatment type was not independently associated with target iPTH achievement, whereas higher baseline iPTH and phosphorus were associated with lower odds of achieving target iPTH. Conclusions: Intravenous paricalcitol was not associated with superior 6-month PTH control compared with intravenous calcitriol in this real-world maintenance hemodialysis cohort. The findings indicate no demonstrated superiority of paricalcitol in this cohort and should not be interpreted as proof of pharmacological equivalence.
- 13 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5483
Open AccessIntravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study
Background/Objectives: Secondary hyperparathyroidism is a frequent component of chronic kidney disease-mineral and bone disorder in maintenance hemodialysis. Calcitriol and paricalcitol are used to suppress intact parathyroid hormone (iPTH), but the comparative advantage of paricalcitol in routine practice remains uncertain. This study compared 6-month biochemical PTH control in patients treated with intravenous calcitriol or intravenous paricalcitol. Methods: In this single-center retrospective cohort study, 312 adult hemodialysis patient files from 2023 to 2025 were screened. Patients who did not receive either intravenous study agent, switched between agents, or did not complete 6 months of treatment with the same agent were excluded. The final cohort included 185 patients, 100 treated with calcitriol and 85 with paricalcitol. The primary endpoint was target iPTH at 6 months, defined as 150–600 pg/mL. Results: Mean age was 58.9 ± 13.6 years, and 106 patients were male. Baseline iPTH was similar in the calcitriol and paricalcitol groups (684 ± 268 vs. 712 ± 291 pg/mL; p = 0.498). At 6 months, iPTH decreased significantly in both groups, with no significant between-group difference in follow-up iPTH (421 ± 214 vs. 398 ± 205 pg/mL; p = 0.456), percentage iPTH reduction (−36.8 ± 22.4% vs. −39.5 ± 24.1%; p = 0.431), or target iPTH achievement (62.0% vs. 60.0%; p = 0.781). Hypercalcemia and hyperphosphatemia rates were also similar. In multivariable analysis, treatment type was not independently associated with target iPTH achievement, whereas higher baseline iPTH and phosphorus were associated with lower odds of achieving target iPTH. Conclusions: Intravenous paricalcitol was not associated with superior 6-month PTH control compared with intravenous calcitriol in this real-world maintenance hemodialysis cohort. The findings indicate no demonstrated superiority of paricalcitol in this cohort and should not be interpreted as proof of pharmacological equivalence.
- 13 June 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-5
ANTI-CCP AND RHEUMATOID FACTOR DO NOT PREDICT RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS
Objective: Rheumatoid arthritis (RA) is a systemic autoimmune disorder marked by chronic inflammation, with considerable heterogeneity in both disease trajectory and therapeutic response. The objective of this study is to assess whether RF and anti-CCP antibodies can serve as predictive markers for treatment outcomes in patients with rheumatoid arthritis undergoing anti-TNF-α therapy. Methods: This retrospective study analyzed 80 RA patients undergoing anti-TNF-α therapy (adalimumab, infliximab, or etanercept), stratified by serologic status: RF-positive alone (n = 27), anti-CCP-positive alone (n = 27), and double-seronegative (n = 26). Comprehensive disease activity assessment was performed using DAS28 scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels at baseline and following 12 months of treatment. Results: All groups showed significant improvement in ESR, CRP, and DAS28 scores after 12 months (p=0.001). No significant differences were observed between the groups in treatment response (p=0.587 for ESR, p=0.767 for CRP, p=0.999 for DAS28). Conclusion: RF and anti-CCP positivity did not significantly influence treatment response to anti-TNF therapy. Further studies with larger cohorts and quantitative antibody measurements are needed to confirm these findings.
- 13 June 2026
- Published by Kocaeli University in Acta Medica Nicomedia
- Vol. 9, 1-5
ANTI-CCP AND RHEUMATOID FACTOR DO NOT PREDICT RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS
Objective: Rheumatoid arthritis (RA) is a systemic autoimmune disorder marked by chronic inflammation, with considerable heterogeneity in both disease trajectory and therapeutic response. The objective of this study is to assess whether RF and anti-CCP antibodies can serve as predictive markers for treatment outcomes in patients with rheumatoid arthritis undergoing anti-TNF-α therapy. Methods: This retrospective study analyzed 80 RA patients undergoing anti-TNF-α therapy (adalimumab, infliximab, or etanercept), stratified by serologic status: RF-positive alone (n = 27), anti-CCP-positive alone (n = 27), and double-seronegative (n = 26). Comprehensive disease activity assessment was performed using DAS28 scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels at baseline and following 12 months of treatment. Results: All groups showed significant improvement in ESR, CRP, and DAS28 scores after 12 months (p=0.001). No significant differences were observed between the groups in treatment response (p=0.587 for ESR, p=0.767 for CRP, p=0.999 for DAS28). Conclusion: RF and anti-CCP positivity did not significantly influence treatment response to anti-TNF therapy. Further studies with larger cohorts and quantitative antibody measurements are needed to confirm these findings.
- Open Access
- 15 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1838167
Borderline liver enzyme patterns and their metabolic–inflammatory signatures: an observational outpatient study
Background and aim: Liver enzyme elevations between one and two times the upper limit of normal (ULN) are common in outpatient practice and often dismissed as clinically insignificant, yet whether this range harbours meaningful subphenotypes, and whether the hepatocellular–cholestatic distinction applies at borderline levels, has not been systematically examined. We investigated whether, in adult outpatients with persistent borderline elevation confirmed using sex-specific ULN, the hepatocellular and cholestatic patterns carry distinct metabolic and inflammatory signatures. Materials and methods: This single-centre observational outpatient study was conducted at Elazığ Fethi Sekin City Hospital between October 2024 and January 2026. Eight hundred adults with standardised fasting biochemistry and haematology panels at baseline and third-month follow-up were analysed. Liver enzymes were classified as normal, borderline, or overtly elevated by the maximum fold-increase above the sex-specific ULN; borderline cases were subcategorised as hepatocellular, cholestatic, or overlap. Clinical, biochemical, inflammatory, and iron parameters were compared, and independent associations were examined using multivariable logistic regression. Results: Enzyme levels were normal in 548 patients (68.5%), borderline in 211 (26.4%), and overtly elevated in 41 (5.1%). Among the 211 borderline patients, 105 (49.8%) exhibited a hepatocellular pattern, 77 (36.5%) a cholestatic pattern, and 29 (13.7%) an overlap pattern. The hepatocellular pattern was associated with higher ferritin, serum iron, and transferrin saturation (TSAT), and a lower AST/ALT ratio; in multivariable analysis, ferritin was the only independent correlate (OR = 1.523; 95% CI: 1.199–1.935; p = 0.001). The cholestatic pattern showed higher HbA1c, higher systemic immune-inflammation index (SII), and lower TSAT; the independent predictors were HbA1c (OR = 1.591; 95% CI: 1.168–2.168; p = 0.003), SII (OR = 2.205; 95% CI: 1.228–3.960; p = 0.008), and TSAT (OR = 0.679; 95% CI: 0.489–0.943; p = 0.021), preserved in the non-diabetic subgroup. The overlap pattern exhibited features of both pure patterns. Conclusion: Persistent borderline liver enzyme elevation can be stratified into biochemically distinct subphenotypes when sex-specific reference ranges are applied. The cholestatic pattern is predominantly associated with glycaemic burden, systemic inflammation, and reduced iron transport, whereas the hepatocellular pattern shows an iron-predominant signature. A pattern-based approach may carry clinical value in outpatient management; findings from full models with limited events-per-variable, particularly for SII, are hypothesis-generating and require longitudinal validation.
- 15 May 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1838167
Open AccessBorderline liver enzyme patterns and their metabolic–inflammatory signatures: an observational outpatient study
Background and aim: Liver enzyme elevations between one and two times the upper limit of normal (ULN) are common in outpatient practice and often dismissed as clinically insignificant, yet whether this range harbours meaningful subphenotypes, and whether the hepatocellular–cholestatic distinction applies at borderline levels, has not been systematically examined. We investigated whether, in adult outpatients with persistent borderline elevation confirmed using sex-specific ULN, the hepatocellular and cholestatic patterns carry distinct metabolic and inflammatory signatures. Materials and methods: This single-centre observational outpatient study was conducted at Elazığ Fethi Sekin City Hospital between October 2024 and January 2026. Eight hundred adults with standardised fasting biochemistry and haematology panels at baseline and third-month follow-up were analysed. Liver enzymes were classified as normal, borderline, or overtly elevated by the maximum fold-increase above the sex-specific ULN; borderline cases were subcategorised as hepatocellular, cholestatic, or overlap. Clinical, biochemical, inflammatory, and iron parameters were compared, and independent associations were examined using multivariable logistic regression. Results: Enzyme levels were normal in 548 patients (68.5%), borderline in 211 (26.4%), and overtly elevated in 41 (5.1%). Among the 211 borderline patients, 105 (49.8%) exhibited a hepatocellular pattern, 77 (36.5%) a cholestatic pattern, and 29 (13.7%) an overlap pattern. The hepatocellular pattern was associated with higher ferritin, serum iron, and transferrin saturation (TSAT), and a lower AST/ALT ratio; in multivariable analysis, ferritin was the only independent correlate (OR = 1.523; 95% CI: 1.199–1.935; p = 0.001). The cholestatic pattern showed higher HbA1c, higher systemic immune-inflammation index (SII), and lower TSAT; the independent predictors were HbA1c (OR = 1.591; 95% CI: 1.168–2.168; p = 0.003), SII (OR = 2.205; 95% CI: 1.228–3.960; p = 0.008), and TSAT (OR = 0.679; 95% CI: 0.489–0.943; p = 0.021), preserved in the non-diabetic subgroup. The overlap pattern exhibited features of both pure patterns. Conclusion: Persistent borderline liver enzyme elevation can be stratified into biochemically distinct subphenotypes when sex-specific reference ranges are applied. The cholestatic pattern is predominantly associated with glycaemic burden, systemic inflammation, and reduced iron transport, whereas the hepatocellular pattern shows an iron-predominant signature. A pattern-based approach may carry clinical value in outpatient management; findings from full models with limited events-per-variable, particularly for SII, are hypothesis-generating and require longitudinal validation.
- 24 April 2026
- Published by Maltepe T脹p Dergisi in Maltepe Tıp Dergisi
The Prognostic Utility of Thyroid‑Stimulating Hormone Levels in Hospitalized COVID‑19 Patients
Giriş amaç COVID-19'un prognozunda çeşitli immünolojik mekanizmalar rol oynar. SARS-CoV-2, yüzeyinde, virüse taç görünümü veren yüzeyinde sivri çıkıntıların varlığıyla karakterizedir. Virüs, epitel hücrelerinde bulunan anjiyotensin dönüştürücü enzim 2 (ACE2) reseptörlerini hedef alır. ACE2 reseptörlerinin ekspresyonu viral girişi kolaylaştırır. ACE2 reseptörlerinin dağılımı farklı organ sistemlerinde değişiklik göstermekle beraber büyük çoğunluğu alveoler epitel hücrelerinde eksprese edilir. Aynı zamanda kalp, böbrek, karaciğer, bağırsaklar ve merkezi sinir sistemi gibi ekstrapulmoner organlarda da bulunurlar. ACE2 reseptörleri tiroid parankiminde de eksprese edilir ve tiroid bezinin de SARS-CoV-2'den etkilenmesine yol açar. TSH düzeylerinin COVID-19'da hastalığın seyri ve sonuçlarına etkisini değerlendirmeyi amaçladık. Materyal-metod Mayıs 2020-Mayıs 2022 arasında hastanemiz Göğüs Hastalıkları kliniğinde yatarak takip edilen SARS-CoV-2 hastaları retrospektif olarak değerlendirildi. Klinik, radyolojik ve laboratuar verileri ile kanıtlanmış COVID-19 pnömonisi bulunan18 yaşın üstünde, çalışma protokolü için gerekli tetkikleri yapılmış olan hastalar dahil edildi. Klinik ve demografik verileri, hastanede yatış süreleri, yoğun bakım gereksinimi olup olmaması ve enfeksiyonun sonucu (iyileşme yada ölüm) kaydedildi. TSH değerleri ile hastalığın seyri, hastanede yatış süreleri, yoğun bakım gereksinimi olup olmaması arasındaki ilişki değerlendirildi. Bulgular Çalışmaya, uygun ve gerekli verileri içeren 211 hasta dahil edildi; Ortalama yaş 63,74(20-95) olarak bulundu. Düşük TSH grubunda 37(%66,1), normal olan grupta 38 (%24,5) hastada yoğun bakım ihtiyacı gelişti. Mortalite oranı düşük TSH grubunda 55,4 (n=31), diğer grupta ise %19,4 (n=30) idi. Ölen ve hayatta kalanlarda ortalama TSH düzeyi anlamlı olarak farklıydı (sırasıyla 0,72±0,74 mIU/L ve 1,60±1,29 mIU/L)(p=<0,001). Sonuçlar Düşük TSH düzeyleri, yoğun bakım ihtiyacı ve hastane içi mortalite ile anlamlı olarak ilişkili bulunmuştur. Mevcut bulgularımız, tiroid fonksiyonlarının COVID-19 seyrini belirlemedeki önemini vurgulamaktadır.
- 24 April 2026
- Published by Maltepe T脹p Dergisi in Maltepe Tıp Dergisi
The Prognostic Utility of Thyroid‑Stimulating Hormone Levels in Hospitalized COVID‑19 Patients
Giriş amaç COVID-19'un prognozunda çeşitli immünolojik mekanizmalar rol oynar. SARS-CoV-2, yüzeyinde, virüse taç görünümü veren yüzeyinde sivri çıkıntıların varlığıyla karakterizedir. Virüs, epitel hücrelerinde bulunan anjiyotensin dönüştürücü enzim 2 (ACE2) reseptörlerini hedef alır. ACE2 reseptörlerinin ekspresyonu viral girişi kolaylaştırır. ACE2 reseptörlerinin dağılımı farklı organ sistemlerinde değişiklik göstermekle beraber büyük çoğunluğu alveoler epitel hücrelerinde eksprese edilir. Aynı zamanda kalp, böbrek, karaciğer, bağırsaklar ve merkezi sinir sistemi gibi ekstrapulmoner organlarda da bulunurlar. ACE2 reseptörleri tiroid parankiminde de eksprese edilir ve tiroid bezinin de SARS-CoV-2'den etkilenmesine yol açar. TSH düzeylerinin COVID-19'da hastalığın seyri ve sonuçlarına etkisini değerlendirmeyi amaçladık. Materyal-metod Mayıs 2020-Mayıs 2022 arasında hastanemiz Göğüs Hastalıkları kliniğinde yatarak takip edilen SARS-CoV-2 hastaları retrospektif olarak değerlendirildi. Klinik, radyolojik ve laboratuar verileri ile kanıtlanmış COVID-19 pnömonisi bulunan18 yaşın üstünde, çalışma protokolü için gerekli tetkikleri yapılmış olan hastalar dahil edildi. Klinik ve demografik verileri, hastanede yatış süreleri, yoğun bakım gereksinimi olup olmaması ve enfeksiyonun sonucu (iyileşme yada ölüm) kaydedildi. TSH değerleri ile hastalığın seyri, hastanede yatış süreleri, yoğun bakım gereksinimi olup olmaması arasındaki ilişki değerlendirildi. Bulgular Çalışmaya, uygun ve gerekli verileri içeren 211 hasta dahil edildi; Ortalama yaş 63,74(20-95) olarak bulundu. Düşük TSH grubunda 37(%66,1), normal olan grupta 38 (%24,5) hastada yoğun bakım ihtiyacı gelişti. Mortalite oranı düşük TSH grubunda 55,4 (n=31), diğer grupta ise %19,4 (n=30) idi. Ölen ve hayatta kalanlarda ortalama TSH düzeyi anlamlı olarak farklıydı (sırasıyla 0,72±0,74 mIU/L ve 1,60±1,29 mIU/L)(p=<0,001). Sonuçlar Düşük TSH düzeyleri, yoğun bakım ihtiyacı ve hastane içi mortalite ile anlamlı olarak ilişkili bulunmuştur. Mevcut bulgularımız, tiroid fonksiyonlarının COVID-19 seyrini belirlemedeki önemini vurgulamaktadır.
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45965
An atypical presentation of NSCLC in a nonsmoker: Shoulder pain and upper extremity DVT: A case report
Rationale: Lung cancer is a leading cause of cancer-related mortality and is often diagnosed late due to nonspecific or extrapulmonary symptoms. Atypical presentations in never-smokers with adenocarcinoma may delay diagnosis. This case highlights the diagnostic value of shoulder pain caused by unprovoked upper extremity deep vein thrombosis (UEDVT) as an early manifestation of thoracic malignancy. Patient concerns: A 62-year-old male nonsmoker presented with a month-long history of progressive right shoulder pain radiating to the neck, without respiratory symptoms or trauma. The pain persisted despite analgesics. Diagnoses: Doppler ultrasonography showed acute thrombosis of the right subclavian, axillary, brachial, and internal jugular veins, explaining the shoulder pain. Contrast-enhanced computed tomography (CT) revealed a right hilar mass compressing vascular structures, and positron emission tomography–CT demonstrated mild hypermetabolism (maximum standardized uptake value = 3.1) without metastasis. Endobronchial biopsy confirmed epidermal growth factor receptor–mutant invasive adenocarcinoma. Interventions: The patient was hospitalized for extensive UEDVT and treated with low-molecular-weight heparin, later switched to the direct oral anticoagulant. No thrombectomy or thrombolysis was required. A multidisciplinary tumor board planned surgical or chemoradiotherapeutic management based on resectability. Outcomes: Symptoms improved with anticoagulation, and the patient remained clinically stable pending oncologic therapy. Lessons: Lung adenocarcinoma may rarely present with isolated shoulder pain as the initial symptom. When UEDVT is identified without an evident provoking factor, underlying malignancy should be thoroughly investigated. Additionally, epidermal growth factor receptor–mutant adenocarcinomas may demonstrate only mild fluorodeoxyglucose uptake on positron emission tomography–CT, emphasizing that low metabolic activity does not exclude cancer.
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45965
Open AccessAn atypical presentation of NSCLC in a nonsmoker: Shoulder pain and upper extremity DVT: A case report
Rationale: Lung cancer is a leading cause of cancer-related mortality and is often diagnosed late due to nonspecific or extrapulmonary symptoms. Atypical presentations in never-smokers with adenocarcinoma may delay diagnosis. This case highlights the diagnostic value of shoulder pain caused by unprovoked upper extremity deep vein thrombosis (UEDVT) as an early manifestation of thoracic malignancy. Patient concerns: A 62-year-old male nonsmoker presented with a month-long history of progressive right shoulder pain radiating to the neck, without respiratory symptoms or trauma. The pain persisted despite analgesics. Diagnoses: Doppler ultrasonography showed acute thrombosis of the right subclavian, axillary, brachial, and internal jugular veins, explaining the shoulder pain. Contrast-enhanced computed tomography (CT) revealed a right hilar mass compressing vascular structures, and positron emission tomography–CT demonstrated mild hypermetabolism (maximum standardized uptake value = 3.1) without metastasis. Endobronchial biopsy confirmed epidermal growth factor receptor–mutant invasive adenocarcinoma. Interventions: The patient was hospitalized for extensive UEDVT and treated with low-molecular-weight heparin, later switched to the direct oral anticoagulant. No thrombectomy or thrombolysis was required. A multidisciplinary tumor board planned surgical or chemoradiotherapeutic management based on resectability. Outcomes: Symptoms improved with anticoagulation, and the patient remained clinically stable pending oncologic therapy. Lessons: Lung adenocarcinoma may rarely present with isolated shoulder pain as the initial symptom. When UEDVT is identified without an evident provoking factor, underlying malignancy should be thoroughly investigated. Additionally, epidermal growth factor receptor–mutant adenocarcinomas may demonstrate only mild fluorodeoxyglucose uptake on positron emission tomography–CT, emphasizing that low metabolic activity does not exclude cancer.
- Open Access
- 9 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4081
An Overlooked Etiology of Acute Kidney Injury: A Clinicopathological Analysis of Phosphate Nephropathy and Review of the Literature
Background: Acute phosphate nephropathy (APN) is an underrecognized cause of acute kidney injury (AKI), typically associated with the use of oral sodium phosphate (OSP)-based bowel preparations. It is characterized by calcium phosphate crystal deposition within the renal tubules and may result in permanent renal impairment. Despite known risks, phosphate-containing solutions are still widely used without sufficient risk stratification. Methods: We retrospectively evaluated 517 native kidney biopsies performed in our nephrology clinic between 2017 and 2022. Among these, 12 patients with unexplained AKI and recent colonoscopy history were identified. In nine cases, non-specific tubular deposits on routine staining prompted further histochemical analysis. All had a history of recent OSP-based bowel cleansing. The use of von Kossa staining confirmed calcium phosphate deposition, consistent with APN. Results: Out of 517 kidney biopsies performed during the study period, 9 patients were diagnosed with APN based on histopathological findings following recent colonoscopy and OSP-based bowel cleansing. The mean age was 58.7 years, and three were female. Hypertension was present in seven patients, diabetes mellitus in three, and epilepsy in two; one patient had no comorbidities. Baseline renal function was normal (mean serum creatinine 0.86 mg/dL) and increased to 1.76 mg/dL at three months post-exposure. All biopsies revealed tubulointerstitial calcium phosphate deposits and interstitial inflammation; mesangial hypercellularity was observed in five cases, tubular atrophy in three, and acute tubular necrosis in one. All samples stained positive with von Kossa staining. Over time, all patients developed chronic kidney disease, and one progressed to end-stage renal disease requiring dialysis. Conclusions: In patients presenting with unexplained AKI and recent OSP-based bowel preparation, APN should be considered in the differential diagnosis. When routine histology is inconclusive, definitive diagnosis may require special histochemical staining. Risk-based restrictions on phosphate-containing agents are warranted to reduce preventable kidney injury.
- 9 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4081
Open AccessAn Overlooked Etiology of Acute Kidney Injury: A Clinicopathological Analysis of Phosphate Nephropathy and Review of the Literature
Background: Acute phosphate nephropathy (APN) is an underrecognized cause of acute kidney injury (AKI), typically associated with the use of oral sodium phosphate (OSP)-based bowel preparations. It is characterized by calcium phosphate crystal deposition within the renal tubules and may result in permanent renal impairment. Despite known risks, phosphate-containing solutions are still widely used without sufficient risk stratification. Methods: We retrospectively evaluated 517 native kidney biopsies performed in our nephrology clinic between 2017 and 2022. Among these, 12 patients with unexplained AKI and recent colonoscopy history were identified. In nine cases, non-specific tubular deposits on routine staining prompted further histochemical analysis. All had a history of recent OSP-based bowel cleansing. The use of von Kossa staining confirmed calcium phosphate deposition, consistent with APN. Results: Out of 517 kidney biopsies performed during the study period, 9 patients were diagnosed with APN based on histopathological findings following recent colonoscopy and OSP-based bowel cleansing. The mean age was 58.7 years, and three were female. Hypertension was present in seven patients, diabetes mellitus in three, and epilepsy in two; one patient had no comorbidities. Baseline renal function was normal (mean serum creatinine 0.86 mg/dL) and increased to 1.76 mg/dL at three months post-exposure. All biopsies revealed tubulointerstitial calcium phosphate deposits and interstitial inflammation; mesangial hypercellularity was observed in five cases, tubular atrophy in three, and acute tubular necrosis in one. All samples stained positive with von Kossa staining. Over time, all patients developed chronic kidney disease, and one progressed to end-stage renal disease requiring dialysis. Conclusions: In patients presenting with unexplained AKI and recent OSP-based bowel preparation, APN should be considered in the differential diagnosis. When routine histology is inconclusive, definitive diagnosis may require special histochemical staining. Risk-based restrictions on phosphate-containing agents are warranted to reduce preventable kidney injury.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9096871
Clinical and Histopathological Correlation of Quantitative HBsAg Levels in Chronic Hepatitis B
Objective: This study is aimed at comparing different clinical forms of chronic hepatitis B (CHB) infection (HBeAg‐negative chronic HBV infection and HBeAg‐positive and HBeAg‐negative CHB patients) and evaluate their demographic, laboratory, virological, and histopathological characteristics, as well as investigate the relationship between quantitative HBsAg (qHBsAg) levels and these parameters. Materials and Methods: This prospective study included a total of 307 patients, comprising 142 HBeAg‐negative chronic HBV infection and 165 CHB patients (39 HBeAg‐positive and 126 HBeAg‐negative). Patient data, including age, sex, ALT, AST, GGT, ALP, total bilirubin, HBV DNA, and qHBsAg levels, were recorded. Additionally, liver biopsy was performed in 111 cases (31 HBeAg‐positive and 80 HBeAg‐negative), and histological activity index (HAI) and fibrosis staging (ISHAK score) were evaluated. Results: No significant differences were observed between HBeAg‐negative chronic HBV infection and CHB patients in age and sex distribution. In the CHB group, ALT and HBV DNA levels were significantly higher ( p = 0.014 and p = 0.025, respectively). Among CHB patients, HBeAg‐positive patients had significantly lower qHBsAg levels than HBeAg‐negative patients (1805 vs. 4028 IU/mL, p < 0.001). Histopathological evaluations showed no significant association between qHBsAg levels and fibrosis severity (ISHAK score > 2) or necroinflammatory activity (HAI > 6). ROC analysis confirmed the limited diagnostic value of qHBsAg for advanced fibrosis (AUC 0.511, 95% CI 0.454–0.569). In HBeAg‐positive patients, a weak negative correlation was found between qHBsAg and HBV DNA levels ( r = –0.388, p = 0.015). Discussion: Our study demonstrated variability in laboratory findings across different forms of CHB. Notably, HBeAg‐positive patients exhibited high HBV DNA levels alongside low qHBsAg levels. The limited efficacy of qHBsAg as a fibrosis marker suggests caution in its clinical use. These findings underscore the importance of considering multiple parameters in assessing liver damage.
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9096871
Open AccessClinical and Histopathological Correlation of Quantitative HBsAg Levels in Chronic Hepatitis B
Objective: This study is aimed at comparing different clinical forms of chronic hepatitis B (CHB) infection (HBeAg‐negative chronic HBV infection and HBeAg‐positive and HBeAg‐negative CHB patients) and evaluate their demographic, laboratory, virological, and histopathological characteristics, as well as investigate the relationship between quantitative HBsAg (qHBsAg) levels and these parameters. Materials and Methods: This prospective study included a total of 307 patients, comprising 142 HBeAg‐negative chronic HBV infection and 165 CHB patients (39 HBeAg‐positive and 126 HBeAg‐negative). Patient data, including age, sex, ALT, AST, GGT, ALP, total bilirubin, HBV DNA, and qHBsAg levels, were recorded. Additionally, liver biopsy was performed in 111 cases (31 HBeAg‐positive and 80 HBeAg‐negative), and histological activity index (HAI) and fibrosis staging (ISHAK score) were evaluated. Results: No significant differences were observed between HBeAg‐negative chronic HBV infection and CHB patients in age and sex distribution. In the CHB group, ALT and HBV DNA levels were significantly higher ( p = 0.014 and p = 0.025, respectively). Among CHB patients, HBeAg‐positive patients had significantly lower qHBsAg levels than HBeAg‐negative patients (1805 vs. 4028 IU/mL, p < 0.001). Histopathological evaluations showed no significant association between qHBsAg levels and fibrosis severity (ISHAK score > 2) or necroinflammatory activity (HAI > 6). ROC analysis confirmed the limited diagnostic value of qHBsAg for advanced fibrosis (AUC 0.511, 95% CI 0.454–0.569). In HBeAg‐positive patients, a weak negative correlation was found between qHBsAg and HBV DNA levels ( r = –0.388, p = 0.015). Discussion: Our study demonstrated variability in laboratory findings across different forms of CHB. Notably, HBeAg‐positive patients exhibited high HBV DNA levels alongside low qHBsAg levels. The limited efficacy of qHBsAg as a fibrosis marker suggests caution in its clinical use. These findings underscore the importance of considering multiple parameters in assessing liver damage.